<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04796142</url>
  </required_header>
  <id_info>
    <org_study_id>IRST 100.40</org_study_id>
    <nct_id>NCT04796142</nct_id>
  </id_info>
  <brief_title>Medication Reconciliation in Oncologic Patients</brief_title>
  <acronym>PROF2</acronym>
  <official_title>An Integrated Model to Increase Medication Recognition and Reconciliation in Oncologic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To improve medication reconciliation in oncologic patients in healthcare transitions through&#xD;
      an alliance between a Cancer Institute and the community pharmacies and a new integrated IT&#xD;
      platform.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial will explore the alliance between a Cancer Institute and the community pharmacies&#xD;
      to improve medication reconciliation in healthcare transitions, and will validate a new&#xD;
      integrated IT platform.&#xD;
&#xD;
      Cancer patients receiving an oncologic treatment will be asked to choose a pharmacy&#xD;
      participating to the trial, and to perform the pharmacological survey before every cycle of&#xD;
      chemotherapy.&#xD;
&#xD;
      This will be sent through the new IT platform to the electronic medical record of IRST, and&#xD;
      the Oncologist will perform the reconciliation.&#xD;
&#xD;
      Data about concomitant medications and possible interactions will be exensively analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 12, 2019</start_date>
  <completion_date type="Anticipated">June 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>medication recognition and reconciliation maintenance</measure>
    <time_frame>At day 1 of each cycle of treatment (each cycle might be 14, 21 or 28 days)</time_frame>
    <description>number of reconciliations per patient</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Medication Reconciliation</condition>
  <arm_group>
    <arm_group_label>Reconciliation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventional trial without drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medication reconciliation</intervention_name>
    <description>medication reconciliation</description>
    <arm_group_label>Reconciliation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult ≥18 years old&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1&#xD;
&#xD;
          -  Patients receiving an anticancer treatment&#xD;
&#xD;
          -  Clear understanding of the Italian language; written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>martina minguzzi</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS IRST</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>alessandro passardi</last_name>
    <phone>0543739100</phone>
    <email>alessandro.passardi@irst.emr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Minguzzi</last_name>
    <phone>0543739100</phone>
    <email>martina.minguzzi@irst.emr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alessandro Passardi</name>
      <address>
        <city>Meldola</city>
        <state>FC</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>alessandro passardi, MD</last_name>
      <phone>0543739100</phone>
      <email>alessandro.passardi@irst.emr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 9, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medication reconciliation</keyword>
  <keyword>IT platform</keyword>
  <keyword>Pharmacies</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD will be shared</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

